Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Nov 2018 This trial has been completed in Bulgaria.
- 24 Oct 2018 This trial has been completed in Austria.
- 20 Mar 2017 New trial record